AskBiography Logo   Latest News  Follow Us on Twitter  Follow Us on Google Buzz  Became Fan - Facebook  Subscribe to RSSRSS   Bookmark and Share

Biogen Idec

Biogen Idec
Company nameBiogen Idec, Inc.
Company typePublic
IndustryBiotechnology
Founded2003
HeadquartersWeston, Massachusetts, U.S.
Key peopleWilliam D. Young (Chairman) George A. Scangos (CEO)
ProductsRituxan
Avonex
Tysabri
Revenue(+) US$ 4.716 billion (2010)
Operating income(-) US$ 1.249 billion (2010)
Net income(-) US$ 899 million (2010)
Total assets(-) US$ 8.092 billion (2010)
Total equity(-) US$ 5.449 billion (2010)
Employees4,850 (2010)

     Home | Company | Biogen Idec



Biogen Idec, Inc. (Nasdaq - BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and Howard Birndorf). Biogen, one of the oldest biotechnology companies, was founded in 1978 in Geneva by several biologists, including Phillip Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase) and Charles Weissmann of Zurich University (who contributed the first product interferon-alpha).

Biogen Idec stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100.

Biogen Idec Video

Weston Corporate Center Topping Off & Sustainable Innovation September 10, 2009 Boston Properties & Biogen Idec
3.72 min. | 5.0 user rating		 Located within the company's research buildings, the Biogen Idec Community Lab is designed to help transform today's young students into the discoverers of tomorrow. The Community Lab, open to local middle and high school students and teachers, operates teaching laboratories at Biogen Idec's headquarters in Cambridge, MA and at its research and corporate campus in San Diego, CA. All programs are offered at no cost to the community.
4.87 min. | 5.0 user rating		 While the approval of Gilenya is important because it is oral (in contrast with the injections in current therapies), its safety profile has yet to be fully understood. The relatively benign FDA label may encourage broader use and give Gilenya a larger than expected Multiple Sclerosis market share of up to 20%. Biogen Idec's answer to this competitive threat will be found in their pipeline, with 2-3 products in Phase 3.
2.98 min. | 0 user rating		 Peter Flinn, Biogen Idec's Senior Director, Global Project Engineering talks to Pharmaceutical Processing's Editor-In-Chief Mike Auerbach about the company's Large-Scale Manufacturing Technology Map Project in Research Triangle Park, North Carolina. The project won the 2010 Operational Excellence Award in the annual Facility of the Year Award competition which is sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.
2.83 min. | 5.0 user rating		 Tysabri was reintroduced to the market in June of 2006. There is no way to tell how many cases of PML occurred from that time until July of 2008. This video is solely based on truth and recorded fact. These numbers can be verified at chefarztfrau.de Biogen Idec reports these figures to the financial sector, the Wall Street Journal, the DOW. These numbers are not readily available to patients or regularly shown/updated at www.tysabri.com. LINK: Only 56000 currently use Tysabri - www.reuters.com
4.40 min. | 5.0 user rating
Andrea DiFabio talks about how finding new treatments for MS - and striving toward curing the disease in the future - inspires her and her colleagues to come to work every day.
1.67 min. | 0 user rating		 Al Sandrock discusses Biogen Idec's work on multiple sclerosis, Parkinson's, Alzheimer's and ALS. We asked him about milestones in his career that have kept him motivated and goals he has for the future.
4.12 min. | 2.33 user rating		 Bill Sibold from Biogen Idec explains why he began working in biotech and how the patients he meets keep him grounded in his work.
2.00 min. | 5.0 user rating		 Biogen Idec's Erika Gill talks about what biotech means to her and why she began working in the industry.
1.52 min. | 1.0 user rating		 During a neurology congress, Biogen Idec launched their brand in Argentina. Eventology implemented a DuoLayer projection, which is a set of animations that enhances the depth effect.
1.05 min. | 1.0 user rating

Latest News : Biogen Idec : Tweet this RSS

Want to Biogen Idec latest news on your twitter account???   sign in with twitter
Biogen Idec     sign in with twitter   ||  Company     sign in with twitter   ||  Economy     sign in with twitter
Recent 52-Week High Exceeded in Shares of Biogen Idec (BIIB) - Benzinga Tweet this news
Benzinga--Shares of -Biogen Idec- (NASDAQ: BIIB) traded at a new 52-week high today of $72.99. Approximately 682000 shares have traded hands today vs. average 30-day volume of 1.7 million shares. -Biogen Idec- is currently trading at $72.97, approximately - Date : Thu, 31 Mar 2011 16:57:59 GMT+00:00
Biogen launches ALS drug trial - Boston Business Journal Tweet this news
Boston Business Journal---Biogen Idec- (Nasdaq: BIIB) and its partner Knopp Biosciences have launched a phase 3 trial for their potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. In connection with the la - Date : Thu, 31 Mar 2011 15:25:41 GMT+00:00
Biogen Idec Stock Hits New 52-Week High (BIIB) - TheStreet.com (blog) Tweet this news
TheStreet.com (blog)--By TheStreet Wire 03/30/11 - 12:05 PM EDT NEW YORK (TheStreet) -- -Biogen Idec- (Nasdaq:BIIB) hit a new 52-week high Wednesday as it traded at $72.11 compared with its previous 52-Week high of $72. -Biogen Idec- is changing hands at - Date : Wed, 30 Mar 2011 16:14:19 GMT+00:00
Protagen to Apply UNIarray Platform for Biogen Idec - Scicasts.com Tweet this news
Scicasts.com--Under the terms of the agreement, Protagen will apply its UNIarray technology platform and expertise in autoantibody research to support retrospective analysis of samples from a -Biogen Idec- clinical trial for the purpose of finding predict - Date : Wed, 30 Mar 2011 09:18:42 GMT+00:00
For Biogen Idec, Peace Is Breaking Out on the Shareholder Front - Wall Street Journal (blog) Tweet this news
Wall Street Journal (blog)--This year, when it comes to eyeing board seats for -Biogen Idec-, Carl Icahn is finally standing pat. For the first time since 2007, the activist investor isn't nominating new candidates to contest for Biogen's board - Date : Mon, 28 Mar 2011 21:11:36 GMT+00:00
Neurologists Anticipate Increased Use of Novartis' Gilenya and Biogen Idec's ... - Business Wire (press release) Tweet this news
Business Wire (press release)--The impact of Gilenya uptake is expected to be split across shares of -Biogen Idec's- Avonex, Bayer's Betaseron, Teva's Copaxone and Pfizer/EMD Serono's Rebif. While neurologists currently state an overal - Date : Tue, 29 Mar 2011 13:44:18 GMT+00:00
Protagen to Apply UNIarray Platform for Biogen Idec - b3c newswire (press release) Tweet this news
b3c newswire (press release)---...- a specialist in in-vitro diagnostics and GMP-compliant protein analysis announced today that they will be using the UNIarray ® Platform to help discover biomarkers in relapsing remitting multiple sclerosis for -Biogen - Date : Tue, 29 Mar 2011 07:34:15 GMT+00:00
Range Tightening in Biogen Idec - TradersHuddle.com Tweet this news
TradersHuddle.com--New York, February 4th (TradersHuddle.com) - Shares of -Biogen Idec- Inc. (NASDAQ:BIIB) closed the trading session at $65.58 placing the price action in a ... - Date : Fri, 04 Feb 2011 11:22:14 GMT+00:00
Roche / Genentech / Biogen Idec: US approval will boost Rituxan dominance - companiesandmarkets.com Tweet this news
companiesandmarkets.com--The FDA has approved Rituxan/MabThera (rituximab; -Biogen Idec-/Genentech/Roche/Chugai/Zenyaku Kogyo) for first-line maintenance treatment for advanced ... - Date : Fri, 04 Feb 2011 11:36:21 GMT+00:00
A Deeper Dive Into Biogen's Revenue Growth - Motley Fool Tweet this news
Motley Fool--On the surface, it looks like -Biogen Idec- (Nasdaq: BIIB) is handling the entrance of Novartis' (NYSE: NVS) new oral multiple ... - Date : Thu, 03 Feb 2011 00:16:38 GMT+00:00

Companies of the NASDAQ-100 index

Activision Blizzard * Adobe * Akamai * Altera * Amazon.com * Amgen * Apollo Group * Apple * Applied Materials * Autodesk * ADP * Baidu * Bed Bath & Beyond * Biogen Idec * BMC Software * Broadcom * C.H. Robinson * CA, Inc. * Celgene * Cephalon * Cerner * Check Point * Cintas * Cisco * Citrix * Cognizant * Comcast * Costco * Dell * Dentsply * DirecTV * Dish Network * eBay * Electronic Arts * Expedia * Expeditors International * Express Scripts * Fastenal * First Solar * Fiserv * Flextronics * FLIR Systems * Foster Wheeler * Garmin * Genzyme * Gilead Sciences * Google * Henry Schein * Hologic * Illumina * Infosys * Intel * Intuit * Intuitive Surgical * J.B. Hunt * Joy Global * KLA-Tencor * Lam Research * Liberty Media * Life Technologies * Linear Technology * Logitech * Marvell * Mattel * Maxim Integrated Products * Microchip Technology * Microsoft * Millicom * Mylan * NetApp * News Corporation * NII * Nvidia * O'Reilly Automotive * Oracle * Paccar * Patterson Companies * Paychex * Priceline.com * Qiagen * Qualcomm * Research In Motion * Ross Stores * SanDisk * Seagate * Sears * Sigma-Aldrich * Staples * Starbucks * Stericycle * Symantec * Teva Pharmaceutical * Urban Outfitters * VeriSign * Vertex Pharmaceuticals * Virgin Media * Vodafone * Warner Chilcott * Wynn Resorts * Xilinx * Yahoo!



Privacy | Sitemap | Micra Hosting | USA Yellow Pages